Get the Stockscreener App
4.34
6.06%
-0.28
After Hours:
4.15
-0.19
-4.38%
Alterity Therapeutics Ltd Adr Stock (ATHE) Latest News
Alterity secures funding to advance MSA drug development - Investing.com India
Alterity Therapeutics raises A$40M in placement - TipRanks
JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Announces Major Securities Placement - TipRanks
Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa
Alterity Therapeutics reports annual general meeting results - Investing.com India
Alterity Therapeutics announces change in company secretary - Investing.com
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):